Market Outlook

Despite the number of therapy options available, metastatic HR-positive/HER2-negative breast cancer remains incurable and is a major cause of mortality and morbidity in women. Additionally, a significant need exists for therapies following hormone resistance in later lines. While the introduction of targeted therapies has helped to improve patient outcomes, a number of unmet needs and treatment gaps persist. Several emerging therapies are also poised to launch in the near term, further increasing competition in a crowded market. As this competition in HR-positive/HER2-negative breast cancer intensifies, novel therapies should more effectively address existing unmet needs to distinguish themselves from their rivals.

Questions Answered

  • What are the treatment drivers most likely to influence a therapy’s uptake for metastatic HR-positive/HER2-negative breast cancer?
  • How do current therapies perform on key drug attributes for metastatic HR-positive/HER2-negative breast cancer?
  • What are the prevailing areas of unmet need and hidden opportunities in this patient population?
  • What trade-offs are surveyed medical oncologists willing to make across different key clinical attributes and price when considering hypothetical new treatment options in metastatic HR-positive/HER2-negative breast cancer?

Product Description

Unmet Need: Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, France, Germany, United Kingdom.

Primary research: Survey of 60 medical oncologists in the United States and 30 medical oncologists in Europe.

Key drugs: Ibrance, letrozole, anastrozole, Faslodex, Kisqali, Verzenio, Afinitor, and exemestane.

Key metrics:

  • Stated versus derived analysis of U.S. and European physician prescribing behavior.
  • Conjoint analysis with U.S. and European physicians includes market simulator.
  • Assessment of current drug performance against treatment drivers and goals.
  • Physician perceptions of unmet need in metastatic HR-positive HER2-negative breast cancer and related diseases/subpopulations.
  • Analysis of remaining drug development opportunities.

Table of contents

  • Detailed, Expanded Analysis (US & EU )
    • Introduction
      • Overview
      • Methodology
      • Rationale for Treatment Drivers and Goals Selection
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
      • Rationale for Drug Selection
    • Treatment Drivers and Goals
      • Key Findings: Attribute Importance
      • Key Findings: Stated vs. Derived Importance
    • Product Performance Against Treatment Drivers and Goals
      • Key Findings
    • Assessment of Unmet Need
      • Key Findings: Unmet Need in Metastatic HR-Positive/HER2-Negative Breast Cancer
      • Key Findings: Unmet Need in Metastatic HR-Positive/HER2-Negative Breast Cancer and Related Indications
    • Opportunity Analysis
      • Areas of Opportunity in the Metastatic HR-Positive/HER2-Negative Breast Cancer Market and Emerging Therapy Insights
        • Opportunity: A New Therapy with Improved Efficacy Attributes
        • Opportunity: A Novel Agent with a Better Safety and Tolerability Profile
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
      • Attribute Importance and Part-Worth Utilities
        • Metastatic Hormone Receptor (HR)-Positive/HER2-Negative Breast Cancer Target Product Profile: Attribute-Level Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Scenario 1
        • Scenario 2
    • Appendix
      • Bibliography

Author(s): Sudha Malhotra, Ph.D; Dana Gheorghe

Sudha Malhotra joined Decision Resource Group in 2018. She is responsible for performing secondary market analysis including patent research, pricing, and clinical trial assessment for major pharmaceutical markets covering a wide range of oncology indications. She obtained her doctorate degree in life sciences from the National Institute of Immunology, New Delhi, India and has authored several original peer-reviewed journal articles. She holds a bachelor’s degree in microbiology and a master’s degree in biomedical sciences both from the University of Delhi, India.

Dana Gheorghe, is a senior business insights analyst on the Oncology team at Decision Resources Group, specializing in non-Hodgkin’s lymphoma and renal cell carcinoma, with expertise in multiple myeloma and metastatic colorectal cancer. Her previous experience includes postdoctoral positions at Imperial College London and the Marie Curie Research Institute. Dr. Gheorghe holds a in cellular biology and biochemistry from the University of Sheffield and a in Molecular Biology from the University of Edinburgh.

Related Reports

Breast Cancer | Landscape & Forecast | Disease Landscape & Forecast

Characterized by high incidence and long treatment durations, the breast cancer market represents a great commercial opportunity for drug developers. CDK4

View Details

Breast Cancer | Unmet Need | Detailed, Expanded Analysis: Advanced/Metastatic Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is a patient population with high unmet need given the poor outcomes associated with current treatment...

View Details

Breast Cancer | Access & Reimbursement | Detailed, Expanded Analysis - Optimizing Market Access Amid an Evolving Landscape for HR+/HER2- Therapies (EU)

MARKET OUTLOOK The lucrative HR-positive, HER2-negative breast cancer market in Europe is fast-moving and competitive. CDK4/6 inhibitors Ibrance (Pfizer), Kisqali (Novar...

View Details

Breast Cancer | Epidemiology | Extrapolated Worldwide Coverage

DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key breast cancer patient popu...

View Details